Using ¹⁸F-NOS PET Imaging to Measure Pulmonary Inflammation in Electronic and Combustible Cigarette Users: A Pilot Study

Introduction

Tobacco use is the world’s greatest preventable cause of morbidity and mortality, accounting for more than 8 million deaths each year (1). Although public awareness of smoking-related risks has increased and tobacco smoking has declined in many countries, electronic cigarette (EC) use has increased dramatically, particularly among youth and young adults (1–3). This increase in EC use is partially driven by the assumption that ECs are safer than conventional cigarettes. Although ECs are often advertised as an alternative smoking cessation tool (4,5), their long-term effectiveness and safety have not been rigorously evaluated (6,7). Given the emergence of the EC or Vaping Product-Associated Lung Injury (EVALI) epidemic in 2019 (8), EC use has become a major public health concern and the adverse pulmonary effects of EC use, particularly relative to that of cigarette smoking, remain unclear.

ECs deliver nicotine by heating e-liquids containing nicotine in a vegetable glycerin/propylene glycol vehicle with flavorings that are vaporized and inhaled, thus delivering nicotine without combusting tobacco. Although the propylene glycol and vegetable glycerin found in e-liquids are commonly used in food and cosmetic products and are regarded as “safe” by the Food and Drug Administration (FDA), e-aerosols contain tobacco-specific nitrosamines (TSNAs), metals, polycyclic aromatic hydrocarbons (PAHs), and volatile organic compounds (VOCs) that are known toxicants and carcinogens (9). As with smoking, several of these EC-related compounds are associated with inflammation, an altered innate immune response, oxidative stress, and cytotoxicity (9–11). However, the existing human literature on the pulmonary effects of EC use is limited and comprised mainly of studies that use invasive approaches (e.g., induced sputum, bronchoalveolar lavage and brushings) that do not adequately assess the impact of EC use on the lungs.

Positron emission tomography (PET) imaging has been used to quantify and track inflammatory responses associated with smoking and EC use in vivo without the need for invasive diagnostic studies (12,13). PET with ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) has been used extensively to detect enhanced glucose metabolic activity of activated immune cells in inflammatory diseases, including pneumonia (14), cystic fibrosis (14), COPD (15), and sarcoidosis (16). Although associations between ¹⁸F-FDG quantification and inflammation have been observed, biologic processes, including fibrosis and neoplasia, utilize glucose and consequently limit the specificity of ¹⁸F-FDG (17). PET radiotracers targeting the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) have also been used to measure pulmonary inflammation (18,19). While these radiotracers were initially considered putative markers of neuroinflammation, their specificity for inflammation is limited (20). Thus, recent efforts have focused on imaging specific aspects of immune regulation and response, such as nitric oxide synthase (NOS) enzymes, with promising results (17,21).

Nitric oxide (NO) plays an important role in immune regulation (22) and is produced by three nitric oxide synthase (NOS) enzymes: neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS). iNOS is associated with acute and chronic inflammatory diseases, including asthma and chronic obstructive pulmonary disease (COPD) (21,23,24), and is expressed in normal lung epithelium (25). There is convergent evidence that iNOS plays a central role in mediating inflammation in combustible cigarette smokers, thereby contributing to smoking-related lung diseases. Preclinical models show that chronic exposure to cigarette smoke also increases iNOS expression in brain (26), whereas pharmacological inhibition of iNOS reverses tobacco-induced lung disease (27). In humans, lung tissue from smokers with lung cancer contains higher iNOS levels than nonsmokers (28). Additionally, preclinical research has provided a mechanistic link between iNOS expression in the lung and inflammatory lung diseases (27,29). These findings strongly support iNOS as a mechanistically relevant target for molecular imaging of lung inflammation and inflammatory lung diseases.

The novel PET radiotracer ¹⁸F-NOS (¹⁸F-6-(1/2)(2-fluoro-propyl)-4-methylpyridin-2-amine) permits the visualization and measurement of in vivo inducible nitric oxide synthase (iNOS) expression (17,30). ¹⁸F-NOS is a radiolabeled version of a reversible iNOS inhibitor with better selectivity than other NOS enzymes (30). ¹⁸F-NOS has been validated in an animal model of lipopolysaccharide-induced lung injury (31) and was used successfully to image iNOS expression in humans to characterize oxidative stress and inflammation in the heart and lungs in vivo (17,30). This study used ¹⁸F-NOS PET lung imaging to quantify group differences in iNOS expression among EC users, cigarette smokers, and never smoke/vape controls. Based on preclinical research showing that exposure to e-liquid vapor and cigarette smoke increases iNOS expression in brain tissue (26,32), we hypothesized that EC users and cigarette smokers would show greater pulmonary iNOS uptake than never smoke/vape controls. Secondary study aims were to assess concentrations of peripheral biomarkers of inflammation (TNF-α, IL-6, IL-8) and to examine their association with ¹⁸F-NOS PET lung imaging parameters.

MATERIALS AND METHODS

Volumes of Interest

Whole-blood pool time activity curves (TACs) were measured using 1 cm³ peak volumes of interest (VOIs) within 2-cm diameter spherical search VOIs within the pulmonary artery, as this blood pool is sufficiently large to minimize partial volume effects and located immediately before blood enters the lungs (Figure 1). Lung uptake TACs were extracted from all lung tissue in the PET field of view (Figure 1).

• Download figure
• Open in new tab

Figure 1.

Representative fused coronal PET/CT images after injecting 207 MBq [¹⁸F]NOS with 2-cm diameter spherical blood pool search VOIs in right atrium (black), pulmonary artery (blue), and left ventricle (red) with PET summed uptake 0-15 s post injection in upper left panel and PET summed 37 to 42 s post injection with lung VOI (cyan) in upper right panel.

RESULTS

Table 1 provides participant characteristics. On average, EC users reported 7 ± 4 vaping episodes/day, with Penn State Electronic Cigarette Dependence Index scores of 6 ± 4, indicating moderate-to-high levels of EC dependence. Cigarette smokers reported smoking 8 ± 4 cigarettes/day, with Fagerström Test for Cigarette Dependence scores of 5 ± 2. These characteristics are consistent with a moderate level of cigarette dependence. There were no significant group differences in age, depression or anxiety scores. There were no significant group differences on injected mass radioactivity dose or plasma-free fraction.

Selection of the pulmonary artery to measure the blood input function is supported by the example fused PET/CT images in Figure 1, where the distribution of ¹⁸F-NOS before entry into the lungs indicates ¹⁸F-NOS entering the right atrium followed by the pulmonary artery before lung entry and subsequent transport to lungs followed by the left ventricle. Average lung ¹⁸F-NOS uptake for all subjects as a function of time is in Figure 2. Kinetic analysis results are in Table 2, where the average estimate of lung blood volume fraction (vB) of 0.15 ± 0.02 (± SD) is consistent with the reported normal lung vB range of 0.14 to 0.19 from ¹⁸F-FDG PET/CT scans(37).

• Download figure
• Open in new tab

Figure 2.

Average lung ¹⁸F-NOS uptake for each group as functions of time with standard deviation error bars. EC = E-Cigarette Users, CIG = Cigarette Smokers, Never Users = Never Smoke/Vape Controls.

¹⁸F-NOS BP_ND values differed significantly between groups, H(2) = 7.50, p = 0.02 (Figure 3). Post-hoc comparisons revealed that EC users had higher BP_ND values than cigarette smokers (p = 0.03) and healthy never smoke/vape controls (p = 0.01). Analysis of ¹⁸F-NOS V_T and K₁ values showed no significant difference between groups (p’s > 0.09).

• Download figure
• Open in new tab

Figure 3.

Boxplot of ¹⁸F-NOS BP_ND by Group. EC Users show higher ¹⁸F-NOS BPnd than never smoke/vape controls (p = 0.01) and cigarette smokers (p = 0.03). EC = E-Cigarette Users, CIG = Cigarette Smokers, Never Users = Never Smoke/Vape Controls. *p < 0.05

Groups did not significantly differ in plasma concentrations of proinflammatory cytokines (p’s > 0.16). We used Spearman’s rank-order correlations to examine the associations between daily smoking/vaping and proinflammatory cytokines and between imaging parameters and levels of proinflammatory cytokines. Among EC users only, there was a positive correlation between ¹⁸F-NOS BP_ND and TNF-α concentration (r_s = 0.87, p = 0.05). Among EC users and cigarette smokers, cigarettes per day and vaping episodes per day correlated with IL-6 levels (r_s= 0.86, p = 0.006). No other correlations were statistically significant.

DISCUSSION

EC use has increased dramatically, particularly among adolescents and young adults, and consequently, there is an urgent need for well-controlled studies of the effects of EC use on the lungs compared to those of cigarette smoking. To date, the existing literature is mainly comprised of in vitro and ex vitro cell culture studies or in vivo studies conducted in rodents, with a few studies of the effects of EC use on the human lung based on invasive approaches that do not assess the global burden of EC use on the lungs. This preliminary study addresses these gaps by using non-invasive, ¹⁸F-NOS PET lung imaging to quantify and compare lung inflammation in exclusive EC users, exclusive cigarette smokers, and never smoke/vape controls. Our preliminary ¹⁸F-NOS PET findings show that EC users have similar delivery of ¹⁸F-NOS to the lung tissue (K₁) and iNOS availability (V_T) similar to that of cigarette smokers and never smoke/vape controls. However, ¹⁸F-NOS BP_ND was significantly higher in the EC group than both cigarette smokers and controls. Moreover, ¹⁸F-NOS BP_ND in EC use was associated with the proinflammatory cytokine TNF-α. Cigarettes per day and vaping episodes per day correlated with IL-6 levels among cigarette smokers and EC users, respectively. To our knowledge, this is the first PET lung imaging study to demonstrate that EC users show a unique PET lung phenotype that is associated with known proinflammatory cytokines.

Although we did not see the expected increase in ¹⁸F-NOS uptake in cigarette smokers, our findings are consistent with recent work by Davis et al. (38) that used bronchoscopy to isolate alveolar macrophages from bronchoalveolar lavage samples in smokers, EC users, and never-smokers. These investigators found that EC use led to greater iNOS expression in alveolar macrophages than in smokers or nonsmokers. Animal and human studies show that iNOS expression is induced in most cell types upon exposure to inflammatory stimuli (39) and is associated with increased pulmonary NO (40). NO mediates neutrophil and macrophage actions that are thought to contribute to pulmonary oxidant stress and acute lung injury (41). Thus, our findings suggest that EC use may alter pulmonary oxidative stress responses and predispose to acute lung injury.

Although the groups showed similar levels of proinflammatory cytokines, EC users showed positive associations between ¹⁸F-NOS PET imaging parameters and TNF-α concentration. TNF-α is a proinflammatory cytokine produced by macrophages and secreted by neutrophil granulocytes at sites of injury (42) and is involved in the inflammatory cascade of acute lung injury (43). Indeed, studies show that proinflammatory cytokines induce iNOS expression in human alveolar cells in response to exposure to fine particulate matter (44). Consistent with our finding of greater ¹⁸F-NOS BP_ND in EC users, we suggest that these correlations provide additional evidence of the altered immune responses in the lungs of EC users.

Several limitations should be considered. First, we did not account for vaping topography, i.e., how an EC is used, including parameters such as puff duration, volume of puff, and duration of EC use episode, or EC device and power settings (e.g., battery voltage and coil resistance). These factors are important in differential exposure to nicotine and toxicants among e-cigarette users (45). While we used individually measured PET radiotracer parent fractions as a function of time to correct for the presence of radiolabelled metabolites in the blood, we could not separate lung ¹⁸F-NOS uptake due to binding of parent ¹⁸F-NOS from any binding of radiolabelled metabolites. Huang et al. asserted “because of [the metabolite’s] polarity, this metabolite is most likely excluded by the lung endothelium from entering the lung parenchyma” (17). Impacts of any lung binding of radiolabelled metabolites on estimates of ¹⁸F-NOS BP_ND will likely be inversely related to the validity of the Huang et al. assumption that polar ¹⁸F-NOS metabolites cannot penetrate lung endothelium. In addition, the sample sizes are small, so additional larger studies are needed to replicate these findings and provide greater statistical power for secondary analyses. Additional data collection is ongoing, as are studies assessing the effects of dual use (e.g., smoking and vaping) and the use of tetrahydrocannabinol (i.e., both combustible and e-liquid use).

Financial Disclosures

Dr. Kranzler is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant to Sobrera Pharmaceuticals; recipient of grant funds and medication supplies from Alkermes for an investigator-initiated study; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka; and a holder of U.S. patent 10,900,082 titled: “Genotype-guided dosing of opioid agonists,” issued 26 January 2021. Drs. Dubroff, Doot, and Mach have received support from the Michael J. Fox Foundation. All other authors do not have disclosures to report.

Key Points

QUESTION: What are the effects of e-cigarette use on pulmonary inflammation compared to combustible cigarette use and never smoking/vaping, as measured in vivo with ¹⁸F-NOS PET imaging?

PERTINENT FINDINGS: In this preliminary PET imaging study, e-cigarette users showed greater ¹⁸F-NOS non-displaceable binding potential (BP_ND) than cigarette smokers and never smoke/vape controls. ¹⁸F-NOS BP_ND significantly correlated with the proinflammatory cytokine TNF-α in e-cigarette users. Additionally, when e-cigarette users and cigarette smokers were pooled together, vaping episodes/cigarettes per day correlated with IL-6 levels.

IMPLICATIONS FOR PATIENT CARE: Preliminary data indicate that e-cigarette users show a unique PET lung imaging phenotype associated with known proinflammatory cytokines, challenging the concept that e-cigarettes are a healthier alternative to cigarettes.